Advertisement
Canada markets open in 3 hours 14 minutes

  • S&P/TSX

    21,714.54
    -297.08 (-1.35%)
     

  • S&P 500

    5,035.69
    -80.48 (-1.57%)
     

  • DOW

    37,815.92
    -570.17 (-1.49%)
     

  • CAD/USD

    0.7260
    -0.0001 (-0.01%)
     

  • CRUDE OIL

    80.54
    -1.39 (-1.70%)
     

  • Bitcoin CAD

    78,419.70
    -6,597.65 (-7.76%)
     

  • CMC Crypto 200

    1,230.70
    -108.37 (-8.09%)
     

  • GOLD FUTURES

    2,300.50
    -2.40 (-0.10%)
     

  • RUSSELL 2000

    1,973.91
    -42.12 (-2.09%)
     

  • 10-Yr Bond

    4.6860
    +0.0720 (+1.56%)
     

  • NASDAQ futures

    17,429.75
    -141.50 (-0.81%)
     

  • VOLATILITY

    16.00
    +0.35 (+2.24%)
     

  • FTSE

    8,150.62
    +6.49 (+0.08%)
     

  • NIKKEI 225

    38,274.05
    -131.61 (-0.34%)
     

  • CAD/EUR

    0.6802
    0.0000 (0.00%)
     

Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference

Atossa Therapeutics, Inc.
·1 min read
Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc.

SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that Chief Executive Officer Steven Quay, M.D., Ph.D., will speak at the Noble Capital Markets Emerging Growth Healthcare Conference on Wednesday, April 17 at 9:00 am ET. The presentation will be available virtually and members of the Company’s leadership team will be available for one-on-one meetings with registered investors of the conference. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

Individuals interested in viewing the live presentation can register for the free event here: Noble Healthcare Conference Registration. A video replay of the presentation will be available for 90 days following the event on the investor relations page of Atossa’s website: https://investors.atossatherapeutics.com and on Channelchek: www.channelchek.com.

About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. For more information, please visit www.atossatherapeutics.com.

Contact
Eric Van Zanten
VP, Investor and Public Relations
610-529-6219
eric.vanzanten@atossainc.com